Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826693 | 1.00 | JAK1 (0.44) | JAK1NAMPTHDAC4MAP4K4PIK3CA | |
| SCHEMBL825965 | 0.95 | HDAC4 (0.44) | JAK1NAMPTHDAC4MAP4K4PIK3CA | |
| SCHEMBL823748 | 0.95 | HDAC4 (0.44) | JAK1NAMPTHDAC4MAP4K4PIK3CA | |
| SCHEMBL3336141 | 0.87 | JAK1 (0.46) | JAK1NAMPTHDAC4PIK3CAMTOR | |
| SCHEMBL3336137 | 0.87 | JAK1 (0.46) | JAK1NAMPTHDAC4PIK3CAMTOR | |
| SCHEMBL826378 | 0.85 | PIK3CA (0.51) | MAP4K4PIK3CAMTORPIK3CG | |
| SCHEMBL823780 | 0.85 | PIK3CA (0.51) | MAP4K4PIK3CAMTORPIK3CG | |
| SCHEMBL3337183 | 0.83 | HDAC4 (0.44) | JAK1NAMPTHDAC4PIK3CAMTOR | |
| SCHEMBL3337179 | 0.83 | HDAC4 (0.44) | JAK1NAMPTHDAC4PIK3CAMTOR | |
| SCHEMBL823662 | 0.81 | PIK3CA (0.52) | HDAC4MAP4K4PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | JAK1 914/4885NAMPT 82/4885HDAC4 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.